Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pharma reputation

- PMLiVE

Vertex continues upward trajectory with French Orkambi deal

Comes on the heels of similar reimbursement deal in England

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Labour Party takes aim at pharma, calls attention to Orkambi row

Proposal to introduce compulsory licensing faces industry criticism

- PMLiVE

Vertex faces rejection of its CF medicines in Scotland

Another rejection over cost-effectiveness

- PMLiVE

Pharma reputation lags behind real value, study suggests

Wide 'opportunity gap' for industry

- PMLiVE

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains

- PMLiVE

Buyers’ Club wants government support on Orkambi imports

Proposes three point plan to work round impasse

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

The Orkambi row explained

Q&A and timeline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links